Foghorn Therapeutics Inc. (FHTX) - Long-Term Debt to Capital

Foghorn Therapeutics (FHTX) possesses exceptional pricing power thanks to its Gene Traffic Control platform for managing gene expression. This chart reflects a current market value of 0.00, although capital remains at risk due to potential failures in primary tests or adverse reactions. Business development relies on partnerships with industry behemoths and strict regulatory oversight within a closed laboratory environment.

To minimize investment risks when analyzing the biotechnology sector, it is critical to evaluate the long-term financing structure. In the absence of profits and given a high cash burn rate, Foghorn Therapeutics (FHTX) relies on equity, as reflected by a long-term debt-to-equity ratio of 0.00. This metric compares liabilities with maturities exceeding one year against equity, determining the company's financial autonomy during the period of costly R&D.